Continuous glucose monitoring in the hospital: an update in the era of COVID-19.

Chikara Gothong, Lakshmi G Singh, Medha Satyarengga, Elias K Spanakis
Author Information
  1. Chikara Gothong: Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine.
  2. Lakshmi G Singh: Division of Endocrinology, Baltimore Veterans Affairs Medical Center, Baltimore.
  3. Medha Satyarengga: Center for Diabetes and Endocrinology, University of Maryland Shore Regional Health, Easton, Maryland, USA.
  4. Elias K Spanakis: Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine.

Abstract

PURPOSE OF REVIEW: Continuous glucose monitoring (CGM) systems are Food and Drug Administration approved devices for the ambulatory setting; however, they remain investigational systems for inpatient use. This review summarizes the most recent and relevant literature on the use of continuous glucose monitoring in the hospital setting.
RECENT FINDINGS: CGM provides real-time glucose data that enable healthcare professionals to make proactive and timelier clinical decisions with regards to diabetes management. CGM devices appear to be safe and accurate systems for glucose monitoring in the hospital setting. Real-time CGM systems and glucose telemetry can decrease hypoglycemia and reduce hyperglycemia in hospitalized patients with diabetes. Remote glucose monitoring decreases the need of frequent Point-of-care checks and personal protective equipment use while also mitigating staff exposure risk which is timely in the advent of the COVID-19 pandemic. Although most nursing staff have limited exposure and training on CGM technology, early studies show that CGM use in the hospital is well received by nurses.
SUMMARY: Given the evidence in the current literature regarding CGM use in the hospital, CGM devices may be incorporated in the inpatient setting.

References

  1. Diabetes Care. 2021 Mar;44(3):847-849 [PMID: 33361145]
  2. Diabetes Care. 2021 Jul;44(7):1641-1646 [PMID: 34099515]
  3. Curr Diab Rep. 2018 Aug 29;18(10):87 [PMID: 30159754]
  4. Lancet. 2020 Mar 28;395(10229):1054-1062 [PMID: 32171076]
  5. J Diabetes Sci Technol. 2019 Jul;13(4):674-681 [PMID: 30636449]
  6. Diabetes Metab Syndr. 2021 Mar-Apr;15(2):499-503 [PMID: 33662836]
  7. Diabetes Care. 2020 Oct;43(10):e137-e138 [PMID: 32769129]
  8. Diabetes Care. 2004 Feb;27(2):553-91 [PMID: 14747243]
  9. J Crit Care. 2021 Jun;63:218-222 [PMID: 32958351]
  10. Diabetes Care. 2020 Jan;43(Suppl 1):S135-S151 [PMID: 31862754]
  11. Diabetes Obes Metab. 2020 Sep;22(9):1678-1682 [PMID: 32533624]
  12. Diabetes Care. 2021 Mar;44(3):e50-e52 [PMID: 33479159]
  13. J Diabetes Sci Technol. 2020 Nov;14(6):1035-1064 [PMID: 32985262]
  14. Endocr Pract. 2021 Aug;27(8):813-818 [PMID: 33894345]
  15. Diabetes Care. 2021 Sep;44(9):e169-e170 [PMID: 34233926]
  16. Crit Care Med. 2021 Apr 1;49(4):636-649 [PMID: 33591015]
  17. J Diabetes Sci Technol. 2017 Sep;11(5):1028-1035 [PMID: 28290224]
  18. Endocr Pract. 2021 Apr;27(4):354-361 [PMID: 33515756]
  19. Diabetes Care. 2021 Apr;44(4):976-982 [PMID: 33574126]
  20. J Diabetes Sci Technol. 2021 May 10;:19322968211008446 [PMID: 33971753]
  21. J Diabetes Sci Technol. 2021 May;15(3):607-614 [PMID: 33435706]
  22. Diabetes Care. 2020 Jul;43(7):e75-e76 [PMID: 32409500]
  23. Diabetes Care. 2020 Nov;43(11):2736-2743 [PMID: 32759361]
  24. Endocrinol Metab (Seoul). 2021 Apr;36(2):240-255 [PMID: 33789033]
  25. Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151 [PMID: 32064853]
  26. Diabetes Care. 2020 Jan;43(Suppl 1):S193-S202 [PMID: 31862758]
  27. Diabetes Care. 2020 Nov;43(11):2730-2735 [PMID: 32641372]
  28. J Clin Endocrinol Metab. 2002 Mar;87(3):978-82 [PMID: 11889147]
  29. Diabetes Res Clin Pract. 2017 Nov;133:178-192 [PMID: 28965029]
  30. J Diabetes Sci Technol. 2018 Jan;12(1):20-25 [PMID: 29237288]
  31. J Clin Endocrinol Metab. 2021 Sep 27;106(10):e4007-e4016 [PMID: 34100545]
  32. Diabetes Care. 2021 Apr;44(4):1055-1058 [PMID: 33563655]
  33. J Diabetes Sci Technol. 2020 Nov;14(6):1135-1136 [PMID: 32476459]
  34. Diabetes Care. 2020 Nov;43(11):2873-2877 [PMID: 32855160]
  35. Diabetes Care. 2018 May;41(5):917-928 [PMID: 29567642]
  36. J Diabetes Sci Technol. 2020 Nov;14(6):1065-1073 [PMID: 33063556]
  37. Diabetes Care. 2020 Nov;43(11):e168-e169 [PMID: 32393587]
  38. Cardiovasc Diabetol. 2020 Jun 11;19(1):76 [PMID: 32527257]
  39. J Diabetes Sci Technol. 2021 Mar 4;:1932296821994586 [PMID: 33660531]
  40. Diabetes Care. 2020 Jan;43(Suppl 1):S111-S134 [PMID: 31862753]

Grants

  1. I01 CX001825/CSRD VA

MeSH Term

Blood Glucose
Blood Glucose Self-Monitoring
COVID-19
Diabetes Mellitus, Type 1
Hospitals
Humans
Pandemics
SARS-CoV-2

Chemicals

Blood Glucose

Word Cloud

Created with Highcharts 10.0.0CGMglucosemonitoringusesystemssettinghospitaldevicesContinuousinpatientliteraturediabetesstaffexposureCOVID-19PURPOSEOFREVIEW:FoodDrugAdministrationapprovedambulatoryhoweverremaininvestigationalreviewsummarizesrecentrelevantcontinuousRECENTFINDINGS:providesreal-timedataenablehealthcareprofessionalsmakeproactivetimelierclinicaldecisionsregardsmanagementappearsafeaccurateReal-timetelemetrycandecreasehypoglycemiareducehyperglycemiahospitalizedpatientsRemotedecreasesneedfrequentPoint-of-carecheckspersonalprotectiveequipmentalsomitigatingrisktimelyadventpandemicAlthoughnursinglimitedtrainingtechnologyearlystudiesshowwellreceivednursesSUMMARY:Givenevidencecurrentregardingmayincorporatedhospital:updateera

Similar Articles

Cited By